Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28611242.
- Also identified by DOI 10.2967/jnumed.116.187625.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this study, we investigated the effects of chronic administration of an inhibitor of the β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) on Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice. <b>Methods:</b> Wild-type (WT) and TG mice received vehicle or BACE inhibitor (60 mg/kg) starting at 7 wk of age. Outcome measures of brain metabolism, neuroinflammation, and amyloid-β pathology were obtained through small-animal PET imaging with <sup>18</sup>F-FDG, <sup>18</sup>F-peripheral benzodiazepine receptor (<sup>18</sup>F-PBR), and <sup>18</sup>F-florbetapir (<sup>18</sup>F-AV45), respectively. Baseline scans were acquired at 6-7 wk of age and follow-up scans at 4, 7, and 12 mo. <sup>18</sup>F-AV45 uptake was measured at 8 and 13 mo of age. After the final scans, histologic measures of amyloid-β (4G8), microglia (ionized calcium binding adaptor molecule 1), astrocytes (glial fibrillary acidic protein), and neuronal nuclei were performed. <b>Results:</b> TG mice demonstrated significant age-associated increases in <sup>18</sup>F-AV45 uptake. An effect of treatment was observed in the cortex (<i>P</i> = 0.0014), hippocampus (<i>P</i> = 0.0005), and thalamus (<i>P</i> < 0.0001). Histology confirmed reduction of amyloid-β pathology in TG-BACE mice. Regardless of treatment, TG mice demonstrated significantly lower <sup>18</sup>F-FDG uptake than WT mice in the thalamus (<i>P</i> = 0.0004) and hippocampus (<i>P</i> = 0.0332). Neuronal nucleus staining was lower in both TG groups in the thalamus and cortex. <sup>18</sup>F-PBR111 detected a significant age-related increase in TG mice (<i>P</i> < 0.0001) but did not detect the treatment-induced reduction in activated microglia as demonstrated by histology. <b>Conclusion:</b> Although <sup>18</sup>F-FDG, <sup>18</sup>F-PBR111, and <sup>18</sup>F-AV45 all detected pathologic alterations between TG and WT mice, only <sup>18</sup>F-AV45 could detect an effect of BACE inhibitor treatment. However, changes in WT binding of <sup>18</sup>F-AV45 undermine the specificity of this effect.
Medical subject headings
- Aging
- Alzheimer Disease
- Alzheimer Disease/diagnostic imaging
- Alzheimer Disease/drug therapy
- Alzheimer Disease/pathology
- Amyloid Neuropathies
- Amyloid Neuropathies/pathology
- Amyloid Precursor Protein Secretases
- Amyloid Precursor Protein Secretases/antagonists & inhibitors
- Amyloid beta-Peptides
- Amyloid beta-Peptides/metabolism
- Aniline Compounds
- Animals
- Aspartic Acid Endopeptidases
- Aspartic Acid Endopeptidases/antagonists & inhibitors
- Brain
- Brain/diagnostic imaging
- Brain/pathology
- Brain Chemistry
- Enzyme Inhibitors
- Enzyme Inhibitors/therapeutic use
- Ethylene Glycols
- Fluorodeoxyglucose F18
- Humans
- Inflammation
- Inflammation/pathology
- Mice
- Mice, Transgenic
- Positron-Emission Tomography
- Radiopharmaceuticals
- Treatment Outcome